Cowen analyst Phil Nadeau lowered the price target on Biogen (NASDAQ: BIIB) to $275.00 (from $400.00) while maintaining a Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

Biogen (BIIB) PT Lowered to $300 at H.C. WainwrightMarch 25, 2019 7:49 AM Mizuho Securities Downgrades Biogen (BIIB) to NeutralMarch 21, 2019 10:06 AM Wells Fargo Downgrades Biogen (BIIB) to Market Perform, Expects Equity to Trade Rang-BoundMarch 21, 2019 9:16 AM Atlantic Equities Downgrades Biogen (BIIB) to NeutralMarch 21, 2019 9:02 AM Biogen (BIIB) option implied volatility low, shares plunge 25% after discontinuing Alzheimer's trialsMarch 21, 2019 8:36 AM Biogen (BIIB) PT Lowered to $280 at Piper JaffrayMarch 21, 2019 8:31 AM Biogen (BIIB) fair value is $241/share without AD - CitiMarch 21, 2019 8:28 AM William Blair Downgrades Biogen (BIIB) to Market PerformMarch 21, 2019 8:27 AM Biogen (BIIB) PT Lowered to $250 at Baird on Alzheimer's FailureMarch 21, 2019 8:20 AM Guggenheim Sees Biogen (BIIB) Down 15-20% After 'Worst Fears Come True'March 21, 2019 8:11 AM Biogen (BIIB) option implied volatility low into discontinuing two Alzheimer's trialsMarch 21, 2019 7:55 AM Biogen (BIIB) puts more active than calls into decision to discontinue the global Phase 3 trials, ENGAGE and EMERGEMarch 21, 2019 7:42 AM Biogen (BIIB) option implied volatility low into decision to discontinue the global Phase 3 trials, ENGAGE and EMERGEMarch 21, 2019 7:38 AM Biogen (BIIB) Resumes Trading, Down 25%March 21, 2019 7:30 AM Biogen (BIIB) to Resume Trading at 7:30 am ETMarch 21, 2019 7:05 AM Biogen (BIIB), Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in AD Due to FutilityMarch 21, 2019 7:01 AM Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s DiseaseMarch 21, 2019 7:01 AM